Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3906 Target Snapshot

Ribosomal protein S6 kinase alpha-2 · SINGLE PROTEIN · Homo sapiens

1,354Compounds
395Assays
10Approved Drugs
655.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q15349. Use UniProt Q15349 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q15349 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ribosomal protein S6 kinase alpha-2 as ChEMBL target CHEMBL3906, mapped to UniProt Q15349. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ribosomal protein S6 kinase alpha-2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3906
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q15349
Ribosomal protein S6 kinase alpha-2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ribosomal protein S6 kinase alpha-2 is the right protein anchor across sources, using UniProt Q15349 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRibosomal protein S6 kinase alpha-2
UniProt AccessionQ15349
Component TypeProtein
Sequence Length733 aa

Ribosomal protein S6 kinase alpha-2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Ribosomal protein S6 kinase alpha-2, mapped to UniProt Q15349. Sequence length is 733 aa.

Mapped IDQ15349
Review nameRibosomal protein S6 kinase alpha-2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

10
Approved
5
Phase III
9
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC50385.0
KI4.0
KD266.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.97 IC50 0.108 Preclinical
CHEMBL3956539 9.74 IC50 0.18 Preclinical
CHEMBL3945993 9.6 IC50 0.25 Preclinical
CHEMBL3903528 9.42 IC50 0.38 Preclinical
CHEMBL3900064 9.38 IC50 0.42 Preclinical
CHEMBL3959915 9.23 IC50 0.59 Preclinical
CHEMBL3955947 9.22 IC50 0.6 Preclinical
CHEMBL4109143 9.22 IC50 0.6 Preclinical
CHEMBL3908561 9.21 IC50 0.62 Preclinical
CHEMBL3972132 9.2 IC50 0.63 Preclinical
Distribution

pChEMBL Value Distribution

27
5.0
44
5.5
47
6.0
49
6.5
57
7.0
78
7.5
55
8.0
21
8.5
13
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

395
Total Assays
353
Tested Compounds
2
Assay Types
Binding — 394 assays, 353 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 295 346 7.1
assay format 51 5 8.1
cell-based format 37 2 5.9
subcellular format 11 0
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine